The World Health Organization (WHO) has included burnout in the International Classification of Diseases, 11th Revision (ICD-11); public health officials may refuse to renew the license of the last abortion provider in Missouri, which would make the state the only one in the country without access to a legal abortion provider; organizations have announced a research initiative to identify why immunotherapy causes diabetes in some patients with cancer.
Emphasizing that burnout is an occupational phenomenon and not a medical condition, the World Health Organization (WHO) has included burnout in the International Classification of Diseases, 11th Revision (ICD-11). According to WHO, burnout can be characterized by 3 dimensions: feelings of energy depletion or exhaustion; increased mental distance from one’s job, or feelings of negativism or cynicism related to one’s job; and reduced professional efficacy. While burnout was also included in ICD-10 in the same category, the definition is now more detailed.
Public officials may refuse to renew the license of Reproductive Health Services of Planned Parenthood in St. Louis, Missouri, the only clinic in the state that performs abortions. If the license is not renewed, Missouri will become the only state in the country to be without access to legal abortion providers. According to Reuters, the state’s Department of Health and Senior Services director Randall Williams indicated that the state will make a decision by Friday. Last week, Missouri’s governor signed a bill banning abortion 8 weeks into pregnancy.
Approximately 1% of patients with cancer receiving immunotherapy develop a disease akin to type 1 diabetes and oncologists have little explanation as to why. On Wednesday, the Parker Institute for Cancer Immunotherapy, JDRF, and the Helmsley Charitable Trust announced that they will launch a 3-year, $10 million research initiative to uncover the root causes of drug-induced diabetes among patients with cancer, reported STAT News. Researchers involved in the initiative hope to eventually identify new treatment strategies to prevent diabetic complications without sacrificing any potential of immunotherapy drugs.